Ascendis Pharma (ASND)
(Real Time Quote from BATS)
$148.00 USD
-3.26 (-2.16%)
Updated Sep 23, 2024 10:08 AM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Ascendis Pharma A/S (ASND) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$192.62 | $289.00 | $157.00 | 27.34% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Ascendis Pharma A/S comes to $192.62. The forecasts range from a low of $157.00 to a high of $289.00. The average price target represents an increase of 27.34% from the last closing price of $151.26.
Analyst Price Targets (13)
Broker Rating
Ascendis Pharma A/S currently has an average brokerage recommendation (ABR) of 1.15 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on 12 recommendations.
Of the 13 recommendations deriving the current ABR, 12 are Strong Buy, representing 92.31% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 10 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.15 | 1.15 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/5/2024 | Not Identified | Not Identified | Hold | Strong Buy |
9/4/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
9/4/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
9/4/2024 | Cantor Fitzgerald & Co | Li Watsek | Strong Buy | Strong Buy |
9/4/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
8/26/2024 | Evercore Partners | Gavin Clark-Gartner | Not Available | Strong Buy |
8/13/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/13/2024 | Goldman Sachs | Paul K Choi | Strong Buy | Strong Buy |
8/12/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
6/25/2024 | Cowen & Co. | Yaron Werber | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.15 |
ABR (Last week) | 1.15 |
# of Recs in ABR | 13 |
Average Target Price | $192.62 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -1.51 |
ASND FAQs
Ascendis Pharma A/S (ASND) currently has an average brokerage recommendation (ABR) of 1.15 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms.
The average price target for Ascendis Pharma A/S (ASND) is $192.62. The current on short-term price targets is based on 8 reports.
The forecasts for Ascendis Pharma A/S (ASND) range from a low of $157 to a high of $289. The average price target represents a increase of $27.34 from the last closing price of $151.26.
The current UPSIDE for Ascendis Pharma A/S (ASND) is 27.34%
Based on short-term price targets offered by 13 analysts, the average price target for Ascendis Pharma A/S comes to $192.62. The forecasts range from a low of $157.00 to a high of $289.00. The average price target represents an increase of 27.34% from the last closing price of $151.26.